Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Division of Health Sciences Research, Department of Medicine, Cedars-Sinai Health System, Los Angeles, California, USA.
Am J Gastroenterol. 2024 Jan 1;119(1):210-213. doi: 10.14309/ajg.0000000000002492. Epub 2023 Sep 1.
We investigated the efficacy and safety of virtual reality (VR) for functional dyspepsia.
Patients were randomized 2:1 between active vs sham VR. Symptoms were assessed using the Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) over 2-week.
Patients in the active VR group had greater numerical improvement in PAGI-SYM scores (mean difference -0.7; P < 0.001) compared with sham VR (mean difference -0.4; P = 0.032). Active VR led to significant improvements for all PAGI-SYM subscales, except lower abdominal pain, whereas sham only improved heartburn/regurgitation and nausea/vomiting. Half of the total patients reported nonserious adverse effects, although only 1 patient withdrew from the study because of adverse effects.
VR is safe and results in significant symptom improvement in functional dyspepsia. Larger trials are warranted.
我们研究了虚拟现实(VR)治疗功能性消化不良的疗效和安全性。
将患者随机分为 2:1 的主动 VR 组和假 VR 组。使用患者胃肠道疾病症状严重程度指数(PAGI-SYM)在 2 周内评估症状。
与假 VR 组相比(平均差值-0.4;P=0.032),主动 VR 组患者的 PAGI-SYM 评分有更大的数值改善(平均差值-0.7;P<0.001)。主动 VR 对除下腹痛外的所有 PAGI-SYM 亚量表均有显著改善,而假 VR 仅改善烧心/反流和恶心/呕吐。尽管只有 1 名患者因不良反应而退出研究,但一半的总患者报告有非严重不良反应。
VR 安全且可显著改善功能性消化不良的症状。需要更大规模的试验。